Actively Recruiting
A Real-World, Prospective Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Patients
Led by Janssen-Cilag Ltd. · Updated on 2026-06-05
200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This observational study focuses on adults with psoriatic arthritis, a joint inflammation condition associated with psoriasis, which causes red, scaly skin patches. The study aims to evaluate how long patients continue treatment with guselkumab over one year in real-world clinical settings. Researchers are interested in understanding treatment persistence and outcomes in routine medical practice, rather than in a controlled clinical trial. Participants diagnosed with psoriatic arthritis who are receiving guselkumab as part of their usual care will be enrolled. The study does not provide any drugs but collects data based on the participants' ongoing treatment decisions made by their rheumatologists. The study tracks treatment persistence up to one year and longer, with no intervention or changes made by the study team. During the study, participants' medical records and treatment data will be collected to monitor how many continue guselkumab after one year and at later time points. Researchers will assess disease activity, symptom changes, and treatment satisfaction through questionnaires and clinical indices at various intervals. Safety data and reasons for treatment changes will also be recorded. The total participation period can extend up to two years with regular data collection based on routine clinical visits.
CONDITIONS
Brief Title
A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a confirmed diagnosis of psoriatic arthritis by a rheumatologist using CASPAR criteria
- Starting guselkumab as first to fourth line bDMARD therapy for psoriatic arthritis
- Initiating guselkumab treatment according to product guidelines
- Treatment decision made by rheumatologist before study inclusion
- Provided oral agreement and did not object to data collection as per French regulations
You will not qualify if you...
- Prior use of interleukin-23 inhibitor treatment
- Receiving two or more targeted therapies for psoriatic arthritis or psoriasis simultaneously
- Contraindications to guselkumab such as hypersensitivity or active infections like tuberculosis
- Unwilling or unable to participate in long-term data collection
- Used investigational drugs or devices within 30 days before study start
- Currently enrolled in other interventional or Janssen-Cilag France-sponsored observational studies
- Under legal guardianship, curatorship, judicial protection, or family authorization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 2 years
Participants who undergo routine care with guselkumab treatment for psoriatic arthritis are observed. Data from routine clinical practice is collected over time to assess treatment persistence and outcomes.
Visits at baseline, and approximately every 3 months up to 24 months (Months 0, 3, 6, 12, 18, and 24)
Trial Site Locations
Total: 1 location
1
Hopital Roger Salengro - CHU Lille
Lille, France, 59037
Actively Recruiting
Research Team
S
Study Contact
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here